Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX-4430 · 1 trial · 1 indication
Change from baseline in inflammatory lesion count after 12 weeks of treatment as compared to placebo.
Incidence of treatment emergent adverse events as compared to placebo.
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| CTX-4430 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Must provide Informed consent. 2. Male or female aged 16 to 44 inclusive. 3. Moderate to severe facial acne vulgaris as defined in the protocol. Exclusion Criteria: 1. Positive testing for HIV, HBsAg, or hepatitis C virus (HCV). 2. Females who are pregnant, lactating, or pl...
CTX-4430 is an investigational small molecule being developed for the treatment of moderate to severe facial acne vulgaris. It is currently in Phase 2 clinical development and has not been approved by the FDA.
CTX-4430 is being developed by CNS Pharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol CNSP.
CTX-4430 is in Phase 2 clinical development. A Phase 2 trial for the treatment of moderate to severe facial acne vulgaris has been completed.
CTX-4430 has been studied in a completed Phase 2 clinical trial with the identifier NCT02385760. This trial enrolled 124 participants with moderate to severe facial acne vulgaris and was conducted in Australia and New Zealand.
CTX-4430 is the primary name used for this investigational drug. No alternative names have been reported in clinical trial records.